Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718826 | 1.00 | CA12 (0.45) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24719054 | 1.00 | CA12 (0.45) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24718268 | 0.81 | CA12 (0.44) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24718393 | 0.78 | SIRT2 (0.50) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24718411 | 0.78 | SIRT2 (0.50) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24718642 | 0.78 | SIRT2 (0.50) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24718387 | 0.78 | CA12 (0.48) | CA12CA9KMT2AKDM4EALDH1A1 | |
| SCHEMBL24718266 | 0.76 | SIRT2 (0.48) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL24719120 | 0.76 | CA12 (0.45) | CA12CA1CA9SIRT2SIRT1 | |
| SCHEMBL11100770 | 0.72 | CA12 (0.58) | CA12CA1CA9KMT2ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612361-B2 | Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding | NORTHWESTERN UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240376050-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | NORTHWESTERN UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | UNITED STATES GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | EED, EZH2, ELP1 | CA12 4697/4885CA1 4649/4885CA9 4598/4885 |
| US-12612361-B2 | Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding | EED, EZH2, EZH1 | CA12 3792/4885CA1 3181/4885CA9 3557/4885 |
| US-20240376050-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | EED, EZH2, ELP1 | CA12 4697/4885CA1 4649/4885CA9 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.